evidence table
Magnesium Glycinate Sleep Quality Randomized Trial Evidence Table
Structured evidence table for Magnesium Glycinate Sleep Quality Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Magnesium Glycinate Sleep Quality Randomized Trial | This case series presents outcomes of the first 51 patients who participated in one such program and aims to add to preliminary evidence regarding the efficacy of a personalized multimodal integrative functional medicine approach to cognitive decline in the context of prior uncontrolled and ongoing controlled trials. | 4 | Kogan Mikhail (2026) | The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series |
| Magnesium Glycinate Sleep Quality Randomized Trial | Management of vascular risk factors (hypertension, hyperlipidemia, diabetes), tobacco and alcohol counseling, and hearing evaluation were conducted through participants’ primary clinicians, consistent with standard dementia prevention guidelines. | 4 | Kogan Mikhail (2026) | The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series |
| Magnesium Glycinate Sleep Quality Randomized Trial | As shown in, participants in the “improved” group were older and more likely to carry at least one APOE4 allele, whereas those in the “progressed” group were younger and started with lower baseline MoCA scores. | 4 | Kogan Mikhail (2026) | The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series |
| Magnesium Glycinate Sleep Quality Randomized Trial | 1 5 - 1 5 - Alzheimer’s disease (AD) and related dementias are significant public health challenges with limited treatment options. | 4 | Kogan Mikhail (2026) | The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series |
Source documents